Gayle Gironda - Inozyme Pharma Senior Officer
| INZY Stock | USD 2.81 0.12 4.46% |
Executive
Gayle Gironda is Senior Officer of Inozyme Pharma
| Address | 321 Summer Street, Boston, MA, United States, 02210 |
| Phone | 857 330 4340 |
| Web | https://www.inozyme.com |
Inozyme Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3569) % which means that it has lost $0.3569 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7942) %, meaning that it created substantial loss on money invested by shareholders. Inozyme Pharma's management efficiency ratios could be used to measure how well Inozyme Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.37 in 2024. Return On Capital Employed is likely to drop to -0.43 in 2024. At this time, Inozyme Pharma's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 2.4 M in 2024, whereas Total Assets are likely to drop slightly above 132.8 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Ege | Seres Therapeutics | 49 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
| MD FAAP | Lumos Pharma | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Alpa Parikh | Lumos Pharma | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
Management Performance
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.36 |
Inozyme Pharma Leadership Team
Elected by the shareholders, the Inozyme Pharma's board of directors comprises two types of representatives: Inozyme Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inozyme. The board's role is to monitor Inozyme Pharma's management team and ensure that shareholders' interests are well served. Inozyme Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inozyme Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Douglas Treco, CEO Chairman | ||
| Henric Bjarke, VP COO | ||
| MS MBA, CFO Officer | ||
| Matthew Winton, Senior COO | ||
| Gayle Gironda, Senior Officer | ||
| Soojin Kim, Senior Officer | ||
| Yves Sabbagh, Chairman VP | ||
| MA MS, Advisor Board | ||
| Demetrios MD, Scientific CoFounder | ||
| MBA MBA, Consultant | ||
| MSc MBA, President, CoFounder | ||
| Stefan Riley, Director Relations |
Inozyme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inozyme Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 95.7 M | ||||
| Shares Outstanding | 64.24 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 96.67 % | ||||
| Number Of Shares Shorted | 3.23 M | ||||
| Price To Book | 2.18 X | ||||
| EBITDA | (74.81 M) | ||||
| Net Income | (71.17 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.